Track Erasca Inc. Common Stock — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Erasca Inc. Common Stock ERAS · Stock Open Erasca Inc. Common Stock in new tab

15.66 USD
EPS
-0.95
P/B
13.48
ROE
-78.25
Beta
0.65
Target Price
24.11 USD
Loading chart...
Key Metrics
Earnings dateMarch 25, 2027
EPS-0.95
Book Value1.16
Price to Book13.48
Debt/Equity12.36
% Insiders5.958%
Estimates
Forward P/E-25.05
Forward EPS-0.62
Target Mean Price24.11

DCF valuation

Model fair value for Erasca Inc. Common Stock (ERAS)
Result
Sign in to run the valuation for ERAS.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
9 analysts · consensus None · mean target 24.11 USD (low 20.00, high 33.00) · as of 10 Nov 2026
Low 20.00
Mean 24.11
High 33.00
Price 15.66
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Erasca Inc. Common Stock Logo Erasca Inc. Common Stock Analysis (ERAS)

United States Health Care Official Website Stock

Is Erasca Inc. Common Stock a good investment? Erasca Inc. Common Stock (ERAS) is currently trading at 15.66 USD. Market analysts have a consensus price target of 24.11 USD. This suggests a potential upside from current levels.

Earnings Schedule: Erasca Inc. Common Stock is expected to release its next earnings report on March 25, 2027. The market consensus estimate for Forward EPS is -0.62.

Investor FAQ

Does Erasca Inc. Common Stock pay a dividend?

No, it does not currently pay a dividend.

What asset class is Erasca Inc. Common Stock?

Erasca Inc. Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be March 25, 2027. The company currently has a trailing EPS of -0.95.

Company Profile

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors. It has license agreement with Guangzhou Joyo Pharmatech Co., Ltd to develop, manufacture, and commercialize certain pan-RAS inhibitors; Medshine Discovery Inc. to develop, manufacture, and commercialize certain pan-KRAS inhibitors; Novartis Pharma AG to develop, manufacture, use, and commercialize naporafenib; NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds; and Asana BioSciences, LLC to develop and commercialize ERAS-007 and certain other related compounds. The company has a clinical trial collaboration and supply agreement with Tango Therapeutics, Inc. for the evaluation of ERAS-0015. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

Exchange Ticker
NMS (United States) ERAS
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion